Brief: Tempus Introduces xM, An Assay To Monitor Immunotherapy Response For Patients With Advanced Cancers
June 2 (Reuters) - Tempus AI Inc TEM.O: TEMPUS INTRODUCES XM, AN ASSAY TO MONITOR IMMUNOTHERAPY RESPONSE FOR PATIENTS WITH ADVANCED CANCERS Source text: ID:nBw3rVlMZa Further company coverage: TEM.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tempus AI
See all newsU.S. STOCKS ON THE MOVE-Tempus AI, Choice Hotels, Palantir
Tempus AI rises after surprise quarterly profit
Tempus AI Q3 revenue slightly beats estimates; raises guidance
Brief: Tempus Receives Ivdr Certification For Xr Rna Sequencing For Solid Tumor Profiling
Brief: Tempus Expands Strategic Collaboration With Bristol Myers Squibb